查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1937850

全球心臟生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Cardiac Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計心臟生物標記市場規模將從 2025 年的 54.4 億美元成長到 2034 年的 269.7 億美元，2026 年至 2034 年的複合年成長率為 19.47%。

由於心血管疾病發病率的上升以及對早期診斷和個人化治療的日益重視，心臟生物標記市場預計將迎來顯著成長。隨著醫療機構致力於改善患者預後，心臟生物標記在心臟疾病的診斷和管理中的作用日益重要。該市場涵蓋多種生物標記物，包括肌鈣蛋白、利鈉肽和其他蛋白質，這些標記物能夠提供有關心臟健康的寶貴資訊。人們對心臟疾病風險因素的認知不斷提高，以及對及時干預的迫切需求，正在推動該領域對先進診斷工具的需求。

技術進步在心臟生物標記市場的發展中發揮關鍵作用，就地檢驗和實驗室診斷技術的創新提高了心臟評估的速度和準確性。高靈敏度檢測方法和多重檢測平台的開發使醫療服務提供者能夠快速獲得全面的心臟狀況，從而有助於做出明智的決策。此外，遠端醫療和遠端監測等數位健康技術的整合正在擴大心臟生物標記檢測的覆蓋範圍，尤其是在醫療資源匱乏的地區。隨著市場的成熟，那些優先考慮創新並投資研發的公司有望佔據更大的市場佔有率。

此外，心臟生物標記市場深受監管趨勢和臨床指南的影響，這些趨勢和指南都在積極推動生物標記在循環系統診療中的應用。隨著醫療體系採用實證實踐，心臟生物標記正日益融入常規臨床工作流程。這種轉變推動了對旨在發現新型生物標記並檢驗其臨床效用價值的研究舉措的投資。對個人化醫療的日益重視將進一步推動對能夠輔助治療決策並改善患者預後的心臟生物標記的需求。能夠使其產品與臨床需求和監管要求相匹配的公司，將在這個充滿活力的市場中佔據有利地位。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球心臟生物標記市場（按類型分類）

  • 市場分析、洞察與預測
  • 心肌肌酸激酶（CK-MB）
  • 肌鈣蛋白（T 和 I）
  • 肌紅蛋白
  • 腦鈉肽（BNP）或NT-proBNP
  • 缺血修飾白蛋白（IMA）
  • 其他

5. 全球心臟生物標記市場（按應用領域分類）

  • 市場分析、洞察與預測
  • 心肌梗塞
  • 鬱血性心臟衰竭
  • 急性冠狀動脈症候群
  • 動脈粥狀硬化
  • 其他

6. 全球心臟生物標記市場（依檢測施行地點分類）

  • 市場分析、洞察與預測
  • 即時檢測
  • 檢查室檢測

7. 全球心臟生物標記市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott Laboratories
    • Siemens Healthcare
    • Thermo Fisher Scientific Inc
    • Becton
    • Dickinson And Co
    • Bio-Rad Laboratories
    • Randox Laboratories
    • Alere Inc
    • Beckman Coulter
    • BioMerieux
    • Roche Diagnostics Corporation
簡介目錄
Product Code: VMR11217049

The Cardiac Biomarkers Market size is expected to reach USD 26.97 Billion in 2034 from USD 5.44 Billion (2025) growing at a CAGR of 19.47% during 2026-2034.

The Cardiac Biomarkers market is poised for significant growth, driven by the increasing prevalence of cardiovascular diseases and the growing emphasis on early diagnosis and personalized treatment approaches. As healthcare providers seek to improve patient outcomes, the role of cardiac biomarkers in diagnosing and managing heart conditions has become increasingly critical. This market encompasses a range of biomarkers, including troponins, natriuretic peptides, and other proteins that provide valuable insights into cardiac health. The rising awareness of heart disease risk factors and the need for timely intervention are propelling the demand for advanced diagnostic tools in this sector.

Technological advancements are playing a pivotal role in the evolution of the Cardiac Biomarkers market, with innovations in point-of-care testing and laboratory diagnostics enhancing the speed and accuracy of cardiac assessments. The development of high-sensitivity assays and multiplex testing platforms is enabling healthcare providers to obtain comprehensive cardiac profiles quickly, facilitating informed decision-making. Additionally, the integration of digital health technologies, such as telemedicine and remote monitoring, is expanding access to cardiac biomarker testing, particularly in underserved populations. As the market matures, companies that prioritize innovation and invest in research and development will likely capture a larger share of the growing demand.

Furthermore, the Cardiac Biomarkers market is increasingly influenced by regulatory developments and clinical guidelines that promote the use of biomarkers in cardiovascular care. As healthcare systems adopt evidence-based practices, the incorporation of cardiac biomarkers into routine clinical workflows is becoming more prevalent. This shift is driving investment in research initiatives aimed at discovering novel biomarkers and validating their clinical utility. As the focus on personalized medicine continues to grow, the demand for cardiac biomarkers that can guide treatment decisions and improve patient outcomes will expand. Companies that align their product offerings with clinical needs and regulatory requirements will be well-positioned to thrive in this dynamic market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others

By Application

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

By Location of Testing

  • Point of Care Testing
  • Laboratory Testing

COMPANIES PROFILED

  • Abbott laboratories, Siemens Healthcare, Thermo Fisher Scientific Inc, Becton, Dickinson And Co, BioRad Laboratories, Randox laboratories, Alere Inc, Beckman Coulter, BioMerieux, Roche Diagnostics Corporation

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIAC BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Myocardial Muscle Creatine Kinase (CK-MB) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Troponins (T and I) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Myoglobin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Brain Natriuretic Peptide (BNPs) or NT-proBNP Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Ischemia Modified Albumin (IMA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIAC BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Myocardial Infarction Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Congestive Heart Failure Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Acute Coronary Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Atherosclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIAC BIOMARKERS MARKET: BY LOCATION OF TESTING 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Location Of Testing
  • 6.2. Point of Care Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Laboratory Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIAC BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By Location Of Testing
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By Location Of Testing
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By Location Of Testing
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By Location Of Testing
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By Location Of Testing
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CARDIAC BIOMARKERS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Abbott Laboratories
    • 9.2.2 Siemens Healthcare
    • 9.2.3 Thermo Fisher Scientific Inc
    • 9.2.4 Becton
    • 9.2.5 Dickinson And Co
    • 9.2.6 Bio-Rad Laboratories
    • 9.2.7 Randox Laboratories
    • 9.2.8 Alere Inc
    • 9.2.9 Beckman Coulter
    • 9.2.10 BioMerieux
    • 9.2.11 Roche Diagnostics Corporation